# Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
Canonical URL: https://biopharmsignal.com/news/KURA/kura-oncology-and-kyowa-kirin-to-present-updated-frontline-ziftomenib-7-3-combination-data-at-eha-2026-congress
Ticker: KURA
Company: Kura Oncology
Source: Kura Oncology
Published: 2026-05-12 13:40 EST
Original Source URL: https://ir.kuraoncology.com
## Summary

– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable responses with median duration of CRc not reached in NPM1-m patients at ~15 months median

## Article Body
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable responses with median duration of CRc not reached in NPM1-m patients at ~15 months median
## Recent Company News
- 2026-06-03 10:53 EST — [Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy](https://biopharmsignal.com/news/KURA/kura-oncology-highlights-darlifarnib-s-potential-as-a-foundational-combination-platform-for-kras-mutant-cancers-and-outlines-development-strategy) — Source: Kura Oncology
- 2026-06-02 12:32 EST — [Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML](https://biopharmsignal.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-publication-in-blood-of-ziftomenib-plus-venetoclax-azacitidine-combination-in-patients-with-r-r-npm1-m-aml) — Source: Kura Oncology
- 2026-05-26 10:02 EST — [Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors](https://biopharmsignal.com/news/KURA/kura-oncology-reports-strong-clinical-activity-and-safety-with-darlifarnib-adagrasib-in-kras-g12c-mutated-solid-tumors) — Source: Kura Oncology
- 2026-05-19 20:02 EST — [Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit](https://biopharmsignal.com/news/KURA/kura-oncology-to-present-at-td-cowen-7th-annual-oncology-innovation-summit) — Source: Kura Oncology
- 2026-05-12 20:02 EST — [Kura Oncology Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/KURA/kura-oncology-reports-first-quarter-2026-financial-results) — Source: Kura Oncology
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)